Food, Global Health 3 min

Tuberculosis: a new lead for biomarkers to assess the risk of transmission

PRESS RELEASE - Tuberculosis is the second leading cause of death from infectious disease in the world after COVID-19. Scientists from INRAE and Inserm have discovered two subsets of neutrophils that play opposing roles in inflammatory responses to infection and could serve as biomarkers to identify individuals at risk of developing a contagious form of the disease. Their findings appear on 21 May in Life Science Alliance.

Published on 21 May 2024

epl betting odds
© CDC - Unsplash

Tuberculosis is a chronic inflammatory disease which most often targets the lungs. It is caused by Mycobacterium tuberculosis and has afflicted humans for thousands of years. Far from a thing of the past, the disease remains all too active throughout the world and killed 1.3 million people[1] in 2022. Monitoring the development of tuberculosis is difficult, and tests do not distinguish between the active (contagious) and latent (non-contagious) forms of the disease. It is estimated that one-third of the world’s population is infected with the latent – and most common – form of TB, which presents no clinical symptoms. Detecting which individuals are likely to transmit the bacteria to others is therefore of imminent importance.

A team of scientists from INRAE and Inserm, with researchers in Brazil and Belgium, have studied neutrophils, a type of white blood cell armed with a toxic arsenal to kill pathogens. A massive concentration of these cells in infected areas, however, can destroy tissue – most often lung tissue in cases of tuberculosis.

The research team discovered two subsets of neutrophils that play opposing roles in the inflammation process triggered by an M. tuberculosis infection: conventional neutrophils, which exacerbate inflammation by producing IL-1β, a pro-inflammatory cytokine, and regulatory neutrophils, which “brake” inflammation using PD-L1 protein to suppress pro-inflammatory T-cell proliferation. This neutrophil subset tempers immune response and prevents lung damage.  Researchers demonstrated that injecting regulatory neutrophils into mice that are highly vulnerable to M. tuberculosis minimised lung tissue lesions. These findings bring to light the risks of prescribing anti-PD-L1 in certain cancer treatments for patients with latent tuberculosis. This type of treatment, sometimes used to reverse the inactivation of an immune system caused by cancer cells, could also reactivate a TB infection by blocking the action of PD-L1.

The scientists also showed that the most virulent strains of the bacteria were able to counteract regulatory neutrophil activity and create a self-benefiting inflammatory environment by inhibiting the production of PD-L1.

These findings represent a step forward in the diagnosis of a patient’s clinical condition, from latent and asymptomatic to active infection, based on concentrations of conventional and regulatory neutrophils in the blood. The detection of neutrophil subsets as biomarkers would make it possible to tailor the prescription of antibiotics to individuals at risk of developing a contagious form of TB. The feasibility of this detection will be further explored by researchers in collaboration with clinicians.

 

[1] Based on the World Health Organization (WHO) Global Tuberculosis Report 2023

 

tuberculosIS WORLDWIDE IN 2022  (2023 WHO report)

  • The reported number of people newly diagnosed with TB was 7.5 million in 2022 (the highest number since WHO began global TB monitoring in 1995).
  • COVID-19 related disruptions caused nearly half a million additional deaths from tuberculosis between 2020 and 2022.
  • Two-thirds of all cases were in eight countries: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of Congo (3.0%).
  • 34 million people received treatment.
  • Treatment success rates have improved: to 88% for people treated for drug-sensitive TB and 63% for people with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB).

 

REFErence

Doz-Deblauwe E., Bounab B., Carreras F. et al. (2024). Dual neutrophil subsets exacerbate or suppress inflammation in tuberculosis via IL-1β or PD-L1. Life Science Alliance, DOI: 10.26508/lsa.202402623

 

INRAE Press Office

Scientific contact

Nathalie Winter Infectious Diseases & Public Health joint research unit (INRAE, Université de Tours)

Centre

Learn more

Food, Global Health

Discovery of a mechanism that allows Staphylococcus aureus to survive in blood

PRESS RELEASE - Staphylococcus aureus (golden staph) is one of the main causes of bacterial infection in France and throughout the world and is particularly responsible for nosocomial infections. Researchers from INRAE, the CEA and CNRS have discovered how this bacterium can survive in the hostile environment of blood. Staphylococcus aureus detects heme, a molecule that is toxic to bacteria, using a specific bio-sensor that then triggers synthesis of a protective barrier on the bacterium’s surface. This mechanism allows the pathogen to survive and propagate in blood, thereby enabling the infection to spread. Discovering how this sensor works opens up prospects for new antibiotic strategies to control Staphylococcus aureus. These results have been published in the journal mBio.

06 May 2024

Food, Global Health

COVID-19: A potential treatment for loss of smell

PRESS RELEASE - One of the most persistent and debilitating symptoms of COVID19 is anosmia or loss of smell. Researchers at INRAE and ENVA have discovered that a corticoid treatment could help restore the olfactory capacities affected by the viral infection. These results, published on 27 February in Brain, Behavior, and Immunity, are a major step forward in understanding and treating this symptom.

27 February 2024

Food, Global Health

Lyme disease: an innovative vaccine strategy to reduce risks caused by ticks

PRESS RELEASE - Ticks are the number one vector for animal diseases and the number two vector for diseases in humans. The most well-known tick-borne disease, Lyme disease, is caused by a bacterium that cycles between ticks and other animals. An innovative vaccine targeting tick microbiota has been tested to reduce tick susceptibility to infection by the bacteria. The work was carried out by INRAE in partnership with France’s Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the National Veterinary School of Alfort. Findings were published on 24 July in the Microbiome journal.

24 July 2023